GRAIL, LLC
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The compan… Read more
GRAIL, LLC (GRAL) - Net Assets
Latest net assets as of December 2025: $2.58 Billion USD
Based on the latest financial reports, GRAIL, LLC (GRAL) has net assets worth $2.58 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.92 Billion) and total liabilities ($344.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.58 Billion |
| % of Total Assets | 88.22% |
| Annual Growth Rate | 23.14% |
| 5-Year Change | -72.66% |
| 10-Year Change | N/A |
| Growth Volatility | 558.88 |
GRAIL, LLC - Net Assets Trend (2018–2025)
This chart illustrates how GRAIL, LLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GRAIL, LLC (2018–2025)
The table below shows the annual net assets of GRAIL, LLC from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.58 Billion | +2.97% |
| 2024-12-31 | $2.50 Billion | -31.34% |
| 2023-12-31 | $3.65 Billion | -21.52% |
| 2022-12-31 | $4.65 Billion | -50.73% |
| 2021-12-31 | $9.43 Billion | +1578.52% |
| 2020-12-31 | $561.84 Million | +2.05% |
| 2019-12-31 | $550.53 Million | -8.30% |
| 2018-12-31 | $600.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to GRAIL, LLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 915090500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $40.00K | 0.00% |
| Other Comprehensive Income | $2.65 Million | 0.10% |
| Other Components | $12.79 Billion | 496.03% |
| Total Equity | $2.58 Billion | 100.00% |
GRAIL, LLC Competitors by Market Cap
The table below lists competitors of GRAIL, LLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FRESHWORKS CL.A DL-00001
F:7DF
|
$1.57 Billion |
|
Muenchener Rueckver Ges
PINK:MURGY
|
$1.57 Billion |
|
Yealink Network Technology Corp Ltd
SHE:300628
|
$1.57 Billion |
|
Adient PLC
NYSE:ADNT
|
$1.57 Billion |
|
Hella KGaA Hueck & Co
XETRA:HLE
|
$1.57 Billion |
|
Unicaja Banco S.A
PINK:UNJCF
|
$1.57 Billion |
|
Hang Zhou Iron & Steel Co Ltd
SHG:600126
|
$1.57 Billion |
|
Mitie Group plc
PINK:MITFF
|
$1.57 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GRAIL, LLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,503,405,000 to 2,577,862,000, a change of 74,457,000 (3.0%).
- Net loss of 408,351,000 reduced equity.
- Other comprehensive income increased equity by 1,204,000.
- Other factors increased equity by 481,604,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-408.35 Million | -15.84% |
| Other Comprehensive Income | $1.20 Million | +0.05% |
| Other Changes | $481.60 Million | +18.68% |
| Total Change | $- | 2.97% |
Book Value vs Market Value Analysis
This analysis compares GRAIL, LLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.68x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 9.01x to 0.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $5.26 | $47.37 | x |
| 2019-12-31 | $4.47 | $47.37 | x |
| 2020-12-31 | $4.54 | $47.37 | x |
| 2021-12-31 | $303.69 | $47.37 | x |
| 2022-12-31 | $149.62 | $47.37 | x |
| 2023-12-31 | $117.42 | $47.37 | x |
| 2024-12-31 | $78.47 | $47.37 | x |
| 2025-12-31 | $70.14 | $47.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GRAIL, LLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -277.47%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.13x
- Recent ROE (-15.84%) is above the historical average (-51.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -45.92% | 0.00% | 0.00x | 1.14x | $-335.76 Million |
| 2019 | -44.48% | 0.00% | 0.00x | 1.15x | $-299.91 Million |
| 2020 | -55.56% | 0.00% | 0.00x | 1.26x | $-368.34 Million |
| 2021 | -13.23% | -8539.39% | 0.00x | 1.03x | $-2.19 Billion |
| 2022 | -116.21% | -9719.35% | 0.01x | 1.21x | $-5.86 Billion |
| 2023 | -40.20% | -1574.23% | 0.02x | 1.25x | $-1.83 Billion |
| 2024 | -80.97% | -1613.92% | 0.04x | 1.19x | $-2.28 Billion |
| 2025 | -15.84% | -277.47% | 0.05x | 1.13x | $-666.14 Million |
Industry Comparison
This section compares GRAIL, LLC's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GRAIL, LLC (GRAL) | $2.58 Billion | -45.92% | 0.13x | $1.57 Billion |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |